Skip to content

Study · Non-randomized trial · n = 10 · 2003

5 results

GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Oliveira JH, Vieira JG, Abucham J, Lengyel AM

Journal of endocrinological investigation1 Mar 2003Cited by 10 (Europe PMC)

PMID12809173 (opens in a new tab)DOI10.1007/bf03345162 (opens in a new tab)PepBankPUB-12809173
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, GHRP‑6 significantly increased ACTH from a basal of 15.5 to a peak of 45.1 pmol/l.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised ACTH, a pituitary stress hormone.

    Peptide
    GHRP-6
    Outcome
    IncreaseACTH response to GHRP-6
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    2 microg/kg · iv · single bolusAs given in this study (human).

    Measurements

    ACTH basal
    15.5 pmol/l
    GHRP-6
    ACTH peak
    45.1 pmol/l
    GHRP-6
    ACTH AUC
    1235.4 pmol/l min(-1)
    GHRP-6

    Source sentences

    Summary
    GHRP-6 was able to increase significantly both ACTH (pmol/l, mean +/- SE; basal: 15.5 +/- 1.7 vs peak: 45.1 +/- 9.3) and cortisol values (nmol/l, basal: 583.0 +/- 90.8 vs peak: 1013.4 +/- 194.6).
    2 context sentences
    Summary · context
    ACTH AUC (pmol/l min(-1)) and cortisol AUC (nmol/l min(-1)) values were 1235.4 and 20577.2, respectively.
    Summary · context
    We studied 10 patients with Cushing's disease (8 female, 2 male; age: 36.7 +/- 4.2 yr), 9 with microadenomas, who were submitted to both GHRP-6 (2 microg/kg iv) and DDAVP (10 micro g i.v.) in bolus administration on 2 separate occasions.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, GHRP‑6 significantly increased cortisol from a basal of 583.0 to a peak of 1013.4 nmol/l.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised cortisol, a stress hormone.

    Peptide
    GHRP-6
    Outcome
    IncreaseCortisol response to GHRP-6
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    2 microg/kg · iv · single bolusAs given in this study (human).

    Measurements

    Cortisol basal
    583 nmol/l
    GHRP-6
    Cortisol peak
    1013.4 nmol/l
    GHRP-6
    Cortisol AUC
    20577.2 nmol/l min(-1)
    GHRP-6

    Source sentences

    Summary
    GHRP-6 was able to increase significantly both ACTH (pmol/l, mean +/- SE; basal: 15.5 +/- 1.7 vs peak: 45.1 +/- 9.3) and cortisol values (nmol/l, basal: 583.0 +/- 90.8 vs peak: 1013.4 +/- 194.6).
    2 context sentences
    Summary · context
    ACTH AUC (pmol/l min(-1)) and cortisol AUC (nmol/l min(-1)) values were 1235.4 and 20577.2, respectively.
    Summary · context
    We studied 10 patients with Cushing's disease (8 female, 2 male; age: 36.7 +/- 4.2 yr), 9 with microadenomas, who were submitted to both GHRP-6 (2 microg/kg iv) and DDAVP (10 micro g i.v.) in bolus administration on 2 separate occasions.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, the ACTH response to GHRP‑6 did not differ significantly from the response to DDAVP.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised ACTH about as much as DDAVP did.

    Peptide
    GHRP-6
    Outcome
    No significant changeACTH response, GHRP-6 versus DDAVP
    Study

    n = 10

    Comparator
    DDAVP
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    2 microg/kg · iv · single bolusAs given in this study (human).

    Measurements

    ACTH peak
    45.1 pmol/l
    GHRP-6
    ACTH peak
    50.5 pmol/l
    DDAVP
    ACTH AUC
    1235.4 pmol/l min(-1)
    GHRP-6
    ACTH AUC
    1627.6 pmol/l min(-1)
    DDAVP

    Source sentences

    Summary
    ACTH and cortisol responses to GHRP-6 and DDAVP did not differ significantly (peak: 45.1 +/- 9.3 vs 50.5 +/- 16.2; AUC: 1235.4 +/- 424.8 vs 1627.6 +/- 639.8).
    1 context sentence
    Summary · context
    We studied 10 patients with Cushing's disease (8 female, 2 male; age: 36.7 +/- 4.2 yr), 9 with microadenomas, who were submitted to both GHRP-6 (2 microg/kg iv) and DDAVP (10 micro g i.v.) in bolus administration on 2 separate occasions.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, the cortisol response to GHRP‑6 did not differ significantly from the response to DDAVP.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised cortisol about as much as DDAVP did.

    Peptide
    GHRP-6
    Outcome
    No significant changeCortisol response, GHRP-6 versus DDAVP
    Study

    n = 10

    Comparator
    DDAVP
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    2 microg/kg · iv · single bolusAs given in this study (human).

    Source sentences

    Summary
    ACTH and cortisol responses to GHRP-6 and DDAVP did not differ significantly (peak: 45.1 +/- 9.3 vs 50.5 +/- 16.2; AUC: 1235.4 +/- 424.8 vs 1627.6 +/- 639.8).
    1 context sentence
    Summary · context
    We studied 10 patients with Cushing's disease (8 female, 2 male; age: 36.7 +/- 4.2 yr), 9 with microadenomas, who were submitted to both GHRP-6 (2 microg/kg iv) and DDAVP (10 micro g i.v.) in bolus administration on 2 separate occasions.
  5. 05HumanNon-randomized trialOther

    In patients with Cushing's disease, peak cortisol after GHRP‑6 correlated positively with peak cortisol after DDAVP (r = 0.87).

    In plain wordsIn people with Cushing's disease, those with a high cortisol peak after GHRP‑6 also had a high peak after DDAVP.

    Peptide
    GHRP-6
    Outcome
    Not applicableCorrelation of peak cortisol after GHRP-6 and DDAVP
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    2 microg/kg · iv · single bolusAs given in this study (human).

    Measurements

    Correlation r
    0.87
    peak cortisol, GHRP-6 versus DDAVP

    Source sentences

    Summary
    There was a significant positive correlation between peak cortisol values after GHRP-6 and DDAVP administration (r = 0.87, p = 0.001).
    1 context sentence
    Summary · context
    We studied 10 patients with Cushing's disease (8 female, 2 male; age: 36.7 +/- 4.2 yr), 9 with microadenomas, who were submitted to both GHRP-6 (2 microg/kg iv) and DDAVP (10 micro g i.v.) in bolus administration on 2 separate occasions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 16 to 19Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 4 times, first on 27 Oct 2026, 18:19 UTC. The status did not change between them.

    Study results updated

  2. Version 15

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Versions 4 to 14

    22 Oct 2026, 02:25 UTC

    The same notice was added 11 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  4. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  5. Version 2

    12 Oct 2026, 12:58 UTC

    Study results updated

  6. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.